Key result
Once-weekly exenatide is well tolerated over 52 weeks, with ~68% reporting adverse events.
Why the study?
The safety of exenatide once weekly in Japanese patients with type 2 diabetes inadequately controlled with oral antidiabetes medications required evaluation over 52 weeks.
Is exenatide once weekly safe and effective over 52 weeks in Japanese patients with type 2 diabetes?
Comparison
Exenatide 10 mcg twice daily vs exenatide 2 mg once weekly, with extension on once weekly
Design
Randomized open-label study with extension phase
Follow-up
52 weeks of treatment plus 10 weeks without treatment
Authors
Loading...
Exenatide once weekly was associated with maintained glycemic control and weight loss in Japanese patients; leaves open need for larger randomized trials before changing practice.
RCT (n=136)
open-label
randomized
Is exenatide once weekly safe and effective over 52 weeks in Japanese patients with type 2 diabetes?
Exenatide once weekly is well tolerated and maintains glycemic control and weight loss up to 52 weeks in Japanese patients with type 2 diabetes.
Onishi et al. (2012) conducted an RCT in type 2 diabetes mellitus (n=136). Exenatide was evaluated on treatment-emergent adverse events during the extension period. Exenatide once weekly for 52 weeks was well tolerated in Japanese patients with type 2 diabetes, with 68% experiencing at least one treatment-emergent adverse event during the extension period.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: